CYRAMZA®

(Ramucirumab)

Documentation

Patented
Approved 2014
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: Antagonist
Target: VEGFR2
Indication Category: Cancer

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA